Cannabis has been used for therapeutic purposes for more than 4,000 years.
Multiple studies have been conducted worldwide, investigating and highlighting the numerous medicinal benefits of this plant. Within professional medical fields, the treatment for illnesses with cannabis derivatives has spread.
The innovative merit of the project is the obtainment of cannabis oils, which contain a sought-after cannabinoids mix for the treatment of various diseases, through a combination of proper procedures for seed selection, plant production and standardized extraction processes.
The company is headed by two founding partners: Sergio Merofa and João Paulo Rocha, both Brazilians. Providing technical support is Master of Molecular Biology and PhD in Neuroscience Dr Renato Malcher. The technical and scientific lead (lead scientific technician) of the project is Eleonora Scosería, owner of Infodynamis, who brings vast experience in the national pharmaceutical sector.
For conducting and carrying out research and development activities, the services of the chemistry department at Pando Technology Park have been secured, providing advice and technical support. The company is already functional and counts with all the necessary facilities located within the Pando Technology Park. We estimate our market entry for 2022.
João Paulo Rocha
Chief Operating Officer (COO)
Helicopter aviator, founder and director of the first cannabinoid pharmaceutical laboratory in South America.
Chief Executive Officer (CEO)
One of the pioneering entrepreneurs in the medical cannabis industry in Uruguay. Partner and CEO of the Grunelabs Group.
The medicinal use of cannabis is an issue currently on the agenda for most countries in the world. Latin America is no exception, as governments in the region debate the legalization of the production and the specific uses of the plant.
By February 2018, medicinal use was regulated and permitted for most countries in the region. But there are still hundreds of cases where cannabis extracts are imported for compassionate medicinal use.
Currently, cannabis extracts with the characteristics produced by Grüne Labs are not available in the local and regional market, nor are the production processes that ensure Pharma-Grade level quality.
Fill out the form with your data. We will contact you to present our investment models.
GrüneLabs is a global biopharmaceutical company with operations in Uruguay, and Portugal.
+598 2291 4543
Departamento de Canelones
Parque Industrial Gardunha Sul
6005-300 | Soalheira